Logotype. Go to startpage

Developed follow-ups with data from sources such as the National Service Platform

TLV presents a new report on how to develop follow-up using data (RWD) from different sources.

The ability to follow-up on the utilisation of pharmaceuticals and treatment effects is a prerequisite for ensuring TLV is able to contribute to the rapid and equal access to new pharmaceuticals and ensuring as many people as possible have access to treatment. Follow-up is also a prerequisite for being able to ensure that the cost of using a pharmaceutical is reasonable in relation to the benefit, not only in subsidy decisions but also throughout the entirety of a pharmaceutical’s life cycle.

The Dental and Pharmaceutical Benefits Agency (TLV) was commissioned by the Swedish government in 2020 to investigate developed follow-ups with data from sources such as the National Service Platform. The assignment was reported in Swedish 2021. This work is a continuation of previous assignments relating to follow-up, reported in December 2018 and October 2020. There is follow-up work in this field planned to be reported by 1 October 2022.

Health care providers and patients expect access to innovative new pharmaceuticals. Since subsidy applications for these pharmaceuticals often include uncertainties about treatment effects and how the pharmaceutical will be utilised, TLV must be able to carry out high quality follow-up.

This report contains the results from eight pilot studies along with the lessons learned from the work on the pilot studies as well as from TLV’s other work to expand the use of data from clinical practice such as considering the legal prerequisites. We also describe where continued work is needed. An in-depth description of the pilot studies is presented in the appendices to this report (in Swedish only except for pilot 3).

Page information

9 December 2020